Cumberland Pharmaceuticals Inc
CPIX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001087294
No open-market purchases or sales by Cumberland Pharmaceuticals Inc insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $16.0M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Cumberland Pharmaceuticals Inc as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −2 vs. Q4 2023
- Shares held
- 2.16M
- −35.0K (−1.6%) vs. Q4 2023
- Total value
- $3.63M
- −$252.7K (−6.5%) vs. Q4 2023
- New holders
- 1
- 5 more added
- Sold out
- 3
- 9 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CPIX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 32 | $16.0M |
| Q1 2026 | 29 | $8.97M |
| Q4 2025 | 27 | $11.8M |
| Q3 2025 | 30 | $10.6M |
| Q2 2025 | 31 | $12.3M |
| Q1 2025 | 33 | $18.1M |
| Q4 2024 | 20 | $4.36M |
| Q3 2024 | 22 | $2.61M |
| Q2 2024 | 23 | $3.18M |
| Q1 2024 | 23 | $3.63M |
| Q4 2023 | 25 | $3.89M |
| Q3 2023 | 21 | $4.17M |
| Q2 2023 | 23 | $3.52M |
| Q1 2023 | 21 | $4.77M |
| Q4 2022 | 23 | $5.61M |
| Q3 2022 | 17 | $5.89M |
| Q2 2022 | 22 | $5.62M |
| Q1 2022 | 26 | $8.17M |
| Q4 2021 | 26 | $13.2M |
| Q3 2021 | 23 | $7.43M |
| Q2 2021 | 28 | $8.36M |
| Q1 2021 | 31 | $9.77M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Cumberland Pharmaceuticals Inc; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 47 | $0 | 0.00% | −91−65.9% | Reduced |
| Huntington National Bank | 1 | $2 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 20 | $34 | 0.00% | +8+66.7% | Added |
| Wells Fargo & Company | 65 | $109 | 0.00% | +2+3.2% | Added |
| Advisor Group Holdings, Inc. | 100 | $168 | 0.00% | +100 | New |
| UBS Group AG | 1,793 | $3.01K | 0.00% | +1,683+1,530.0% | Added |
| Oakworth Capital, Inc. | 3,052 | $5.13K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 3,622 | $6.08K | 0.00% | +87+2.5% | Added |
| Tower Research Capital LLC (TRC) | 5,747 | $9.65K | 0.00% | +119+2.1% | Added |
| Morgan Stanley | 11,274 | $18.9K | 0.00% | 00.0% | Unchanged |
| Cresset Asset Management, LLC | 12,025 | $20.2K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 16,338 | $27.4K | 0.00% | −1,851−10.2% | Reduced |
| Two Sigma Advisers, LP | 23,000 | $38.6K | 0.00% | −400−1.7% | Reduced |
| Two Sigma Investments, LP | 32,430 | $54.5K | 0.00% | −600−1.8% | Reduced |
| State Street Corp | 33,700 | $56.6K | 0.00% | −6,090−15.3% | Reduced |
| Bank of New York Mellon Corp | 75,268 | $126.5K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 84,522 | $142.0K | 0.00% | −752−0.9% | Reduced |
| BlackRock Inc. | 110,564 | $185.7K | 0.00% | −426−0.4% | Reduced |
| Acadian Asset Management LLC | 188,164 | $315.0K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 286,655 | $481.6K | 0.01% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 357,615 | $600.8K | 0.00% | −8,319−2.3% | Reduced |
| Vanguard Group Inc | 374,251 | $628.7K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 542,663 | $912.0K | 0.00% | −7,200−1.3% | Reduced |
| Wiley Bros.-Aintree Capital, LLC | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −237−100.0% | Sold out |